Expensify Inc vs InMode Ltd — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while InMode Ltd trades at $14.21 (market cap $809.93M). The key difference: InMode Ltd is far larger — about 3.9× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and InMode Ltd for 28 Days on average.
| EXFY | INMD | |
|---|---|---|
Market Cap | $208.82M | $809.93M |
Volume | 456,102 | 365,490 |
Sector | Technology | Health |
52-Week High | $2.72 | $16.62 |
52-Week Low | $0.75 | $12.76 |
Typical Hold Time | 41 Days | 28 Days |
Enterprise Value | $148.44M | $313.27M |
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.30, up 1.32% with a bullish technical signal from moving averages. The company shows improving fundamentals with Q1 and Q2 2026 earnings beats and positive operating cash flow of $20.09M in 2025. Recent business developments include AI-native ERP integrations and European card expansion, signaling growth initiatives. However, the stock carries a high P/E ratio of 258.82 and negative profitability metrics, presenting a mixed investment case.
The outlook remains cautiously optimistic with analyst consensus pointing to significant upside (target $13.75), but investors face risks from persistent net losses and competitive pressures. The key opportunity lies in the company's strategic pivot to AI-driven solutions and international expansion, though execution risks and valuation concerns warrant careful monitoring.
InMode (INMD) trades at $14.08, up 0.5% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 76.5% gross margins and 20.7% net income margin, though Q1 2026 earnings missed expectations. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.
Investment outlook is cautiously optimistic with attractive valuation metrics (P/E 11.6, EV/EBITDA 4.5) offset by near-term revenue stagnation. Key risks include US platform sales decline and management capital allocation concerns. Analyst consensus leans neutral with 45% buy ratings and 55% hold, suggesting potential upside if the acquisition materializes or international growth accelerates.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →